Pharma task force urges Health Canada to streamline regulatory reviews as part of suite of recommendations
The initial focus will be on veterinary drugs and pediatric medication, with the list of regulators including the U.S. Food and Drug Administration, the European Medicines Agency and Australia’s Therapeutic Goods Administration.The task force report suggests more drugs should be included, such as those treating cancer and vaccines. It suggests the first such reviews should start by the end of the year.On the AI investments, the federal government announced in June it would invest up to $100-million in an Ontario-based health data initiative called Vital, based at St.
- ▪The initial focus will be on veterinary drugs and pediatric medication, with the list of regulators including the U.S.
- ▪Food and Drug Administration, the European Medicines Agency and Australia’s Therapeutic Goods Administration.The task force report suggests more drugs should be included, such as those treating cancer and vaccines.
- ▪It suggests the first such reviews should start by the end of the year.On the AI investments, the federal government announced in June it would invest up to $100-million in an Ontario-based health data initiative called Vital, based at St.
The Globe and Mail publishes from Canada and files mainly under world. We currently carry 1,728 of its stories.
Opening excerpt (first ~120 words) tap to expand
Open this photo in gallery:The offices of Health Minister Marjorie Michel, shown in Ottawa in June, and Industry Minister Mélanie Joly said the government will carefully consider the task force's recommendations.Adrian Wyld/The Canadian PressShareSave for laterPlease log in to bookmark this story.Log InCreate Free AccountOttawa’s pharmaceutical-industry task force is urging Health Canada to rely more on the review work of foreign regulators and invest more in health data infrastructure, as part of a suite of recommendations that aim to help Canada navigate geopolitical pressures on the pharmaceutical sector.The task force, whose more than two dozen members are made up mainly of the Canadian heads of patented drug companies, was formed in March to advise the federal government on how to…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Globe and Mail.
Discussion
0 commentsMore from The Globe and Mail
